Clinical Trial Update: Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma [Phase 2]

View source ↗

Summary

Phase 2 trial update for Cinrebafusp Alfa combined with ramucirumab and paclitaxel in HER2-high gastric/GEJ adenocarcinoma, and Cinrebafusp Alfa with tucatinib …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Cinrebafusp alfa (cinrebafusp alfa)
• PACLITAXEL (PACLITAXEL)
• Ramucirumab (ramucirumab)
• Tucatinib (tucatinib)

Snippet

Sponsor: Pieris Pharmaceuticals, Inc. | Conditions: HER2-positive Gastric Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING